{"entity":{"id":"lbl-034","kind":"drug","name":"LBL-034","aka":[],"tldr":"LBL-034 is an experimental bispecific T-cell engager from Nanjing Leads Biolabs, in phase 2 trials for multiple myeloma.","summary":"LBL-034 is a bispecific T-cell engager (2:1 format) from Nanjing Leads Biolabs. A T-cell engager with two binding sites for GPRC5D and one for CD3 that directs T cells to GPRC5D-positive myeloma cells. Its furthest stage is phase 2, for multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase I/II trial in relapsed/refractory multiple myeloma in China (NCT06049290, recruiting). FDA Orphan Drug (Oct 2024) and Fast Track (Jan 2026) per company. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Nanjing Leads Biolabs: leadsbiolabs.com","url":"https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js"},{"label":"Nanjing Leads Biolabs: leadsbiolabs.com","url":"https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js"},{"label":"ClinicalTrials.gov: trials of LBL-034","url":"https://clinicaltrials.gov/search?intr=LBL-034"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["gprc5d","cd3"],"drugs":[],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06049290"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"LBL-034","modality":"Bispecific T-cell engager (2:1 format)","mechanism":"A T-cell engager with two binding sites for GPRC5D and one for CD3 that directs T cells to GPRC5D-positive myeloma cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lbl-034/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}],"trial":[{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct06049290/"}]}}